A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)

NCT00578786 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

383

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: ambrisentan

Sponsor

Gilead Sciences